Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1Phase 2/3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 512Specimen Handling 381Carboplatin 371Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 302Cyclophosphamide 295Radiotherapy 254Paclitaxel 252Biopsy 235Gemcitabine 229Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 154Rituximab 151Fluorouracil 148venetoclax 142atezolizumab 141Docetaxel 141Drug Therapy 140Etoposide 138Doxorubicin 131Ipilimumab 125Radiosurgery 118Lenalidomide 117Prednisone 116Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hyperthermia, Induced × 1 year × Clear all
NCT07062055 2026-05-08

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
54 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00929214 2025-12-17

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡